Anti-HIV Immunoglobulin in Prevention of Maternal-Fetal HIV Transmission: Pediatric AIDS Clinical Trials Group protocol 185 (PACTG) - Catalog


Anti-HIV Immunoglobulin in Prevention of Maternal-Fetal HIV Transmission: Pediatric AIDS Clinical Trials Group protocol 185 (PACTG)

Accession Number




Related studies

BSI Study IDs


Is public use dataset



Has Study Datasets


Has Specimens


Specimen ID Type


Study Website

The Framingham Heart Study Group requires that the requestor must obtain full or expedited IRB/Ethics Committee review and approval to obtain these data. Waivers or a determination that the research is exempt from ethical regulations do not suffice.


Study type

Clinical Trial

Collection Type

Open BioLINCC Study

Cohort type



Drug: immunoglobulins

Study Open Date (Data)


Study Open Date (Specimens)


Date materials available


Last updated


Study period

1991 - 1997

Study Contacts
NHLBI Division



Blood Disease

HIV study classification


COVID study classification


Pre-Website # of Specimens Shipped


# of Returned Specimens



Acquired Immunodeficiency Syndrome
Disease Transmission, Vertical
HIV Infections


To determine if HIV hyperimmune globulin (HIVIG) given to HIV-positive pregnant women during the second and third trimester of pregnancy reduced the likelihood of maternal-fetal HIV transmission.


Several studies have identified maternal, obstetrical, and infant characteristics associated with perinatal transmission of human immunodeficiency virus type 1 (HIV-1). However, these studies were conducted primarily before the widespread use of zidovudine for the prevention of perinatal transmission. Few studies have identified risk factors for transmission among HIV-1–infected women and infants who are receiving zidovudine, yet such information is critical to the development of new interventions to reduce the risk of perinatal transmission further.


A total of 501 HIV-1–infected women who were 20 to 30 weeks pregnant, who had CD4+ lymphocyte counts of no more than 500 per cubic millimeter, and who were receiving zidovudine as prescribed by their physicians. Of these, 4 were lost to follow-up before delivery, resulting in a study population of 497 women. There were 505 live-born infants, including 9 sets of twins and 487 singletons, and 1 stillborn infant.


The study was a multicenter, randomized, controlled phase 3 clinical trial conducted between October 1993 and March 1997 at 53 clinical sites in the contiguous United States and Puerto Rico. Study investigators evaluated whether prophylaxis with zidovudine combined with HIV-1 hyperimmune globulin (HIVIG) at a dose of 200 mg per kilogram of body weight administered intravenously to the women each month during pregnancy and once to the neonates at birth would lower the risk of perinatal HIV-1 transmission more than would zidovudine and intravenous infusions of immune globulin without HIV-1 antibody, at a dose of 200 mg per kilogram. Detailed information on antenatal and obstetrical variables was collected during the trial, plasma and peripheral blood cells from blood draws were collected and laboratory assays were performed at several points during the women's pregnancies to determine maternal plasma levels of HIV-1 RNA, viral titers in quantitative cultures of peripheral-blood mononuclear cells, CD4+ lymphocyte counts, and quantitative HIV-1 p24 antibody levels. Isolates were retained from HIV quantitative cultures. The mother and infant were followed for up to 78 weeks post-partum and additional blood samples and clinical variables were collected. This allowed evaluation of the independent contribution of potential risk factors for perinatal transmission of HIV-1 in a population of women and infants who received zidovudine.


The unexpectedly low transmission confirmed that zidovudine prophylaxis is highly effective, even for women with advanced HIV disease and prior zidovudine therapy, although it limited the study's ability to address whether passive immunization diminishes perinatal transmission (J Infect Dis 1999: 179: 567-75). There were no significant differences between the group that received HIV-1 hyperimmune globulin and the group that received intravenous immune globulin with respect to base-line maternal, obstetrical, and infant characteristics or rates of HIV-1 transmission. Since the rates of perinatal HIV-1 transmission and the clinical and laboratory characteristics were similar in the two groups, data for all women were combined in all subsequent analyses of risk factors. The maternal plasma HIV-1 RNA level was the best predictor of the risk of perinatal transmission of HIV-1. Antiretroviral therapy that reduces the HIV-1 RNA level to below 500 copies per milliliter appears to minimize the risk of perinatal transmission as well as improve the health of the women (NEJM 1999; 341:385-393).

Disease classification


Stiehm ER, Lambert JS, Mofenson LM, Bethel J, Whitehouse J, Nugent R, Moye J Jr, Glenn Fowler M, Mathieson BJ, Reichelderfer P, Nemo GJ, Korelitz J, Meyer WA 3rd, Sapan CV, Jimenez E, Gandia J, Scott G, O'Sullivan MJ, Kovacs A, Stek A, Shearer WT, Hammill H. Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: results of Pediatric AIDS Clinical Trials Group protocol 185. J Infect Dis. 1999 179:567-75.

Lambert JS, Mofenson LM, Fletcher CV, Moye J Jr, Stiehm ER, Meyer WA 3rd, Nemo GJ, Mathieson BJ, Hirsch G, Sapan CV, Cummins LM, Jimenez E, O'Neill E, Kovacs A, Stek A. Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus (HIV) immunoglobulin administered to HIV-infected pregnant women and their newborns. Pediatric AIDS Clinical Trials Group Protocol 185 Pharmacokinetic Study Group. J Infect Dis. 1997 175:283-91.

Mofenson LM, Lambert JS, Stiehm ER, Bethel J, Meyer WA 3rd, Whitehouse J, Moye J Jr, Reichelderfer P, Harris DR, Fowler MG, Mathieson BJ, Nemo GJ. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team. N Engl J Med. 1999 341:385-93.

Lambert JS, Watts DH, Mofenson L, Stiehm ER, Harris DR, Bethel J, Whitehouse J, Jimenez E, Gandia J, Scott G, O'Sullivan MJ, Kovacs A, Stek A, Shearer WT, Hammill H, van Dyke R, Maupin R, Silio M, Fowler MG. Risk factors for preterm birth, low birth weight, and intrauterine growth retardation in infants born to HIV-infected pregnant women receiving zidovudine. Pediatric AIDS Clinical Trials Group 185 Team. AIDS. 2000 14:1389-99.

Watts DH, Lambert J, Stiehm ER, Harris DR, Bethel J, Mofenson L, Meyer WA 3rd, Mathieson B, Fowler MG, Nemo G; PACTG 185 Study Team. Progression of HIV disease among women following delivery. J Acquir Immune Defic Syndr. 2003 33:585-93.

Lambert JS, Harris DR, Stiehm ER, Moye J Jr, Fowler MG, Meyer WA 3rd, Bethel J, Mofenson LM. Performance characteristics of HIV-1 culture and HIV-1 DNA and RNA amplification assays for early diagnosis of perinatal HIV-1 infection. J Acquir Immune Defic Syndr. 2003 34:512-9.

Lambert JS, Moye J Jr, Plaeger SF, Stiehm ER, Bethel J, Mofenson LM, Mathieson B, Kagan J, Rosenblatt H, Paxton H, Suter H, Landay A. Association of selected phenotypic markers of lymphocyte activation and differentiation with perinatal human immunodeficiency virus transmission and infant infection. Clin Diagn Lab Immunol. 2005 12:622-31.

Mat types

Isolates from Culture

The study population available in BioLINCC study data may be lower than total study enrollment due to Informed Consent restrictions and other factors.

  • Subjects

    Mothers: 497

    Infants: 506

    Last Modified: Nov. 1, 2023, 4:05 p.m.
  • Age

    Last Modified: Nov. 1, 2023, 4:05 p.m.
  • Sex

    Last Modified: Nov. 1, 2023, 4:05 p.m.
  • Race
    Black, not Hispanic25851.91
    Unknown Value6813.68

    Last Modified: Nov. 1, 2023, 4:05 p.m.

Please note that biospecimen availability is subject to review by the NHLBI, BioLINCC, and the NHLBI Biorepository. Certain biospecimens may not be made available for your request. Section 3 of the BioLINCC handbook describes the components of the review process

  • Material Types

    Last Modified: Nov. 30, 2015, 1:23 p.m.
  • General Freeze/Thaw Status
  • Visits (Vials)


    Mother - Labor/Delivery4,3998781,3296,606
    Mother - Pre-entry4,285881525,218
    Mother - Entry4,6709011,4036,974
    Mother - Infusion4,4468371,3666,649
    Mother - Week 6123015
    Mother - Week 123,634753684,455
    Mother - Week 263,8167201,1575,693
    Mother - Week 483,021588853,694
    Mother - Week 782,733518603,311
    Infant - Birth3,7962,127745,997
    Infant - Week 11927046
    Infant - Week 28971,35682,261
    Infant - Week 61,3321,583712,986
    Infant - Week 121,0551,420192,494
    Infant - Week 161,0121,41092,431
    Infant - Week 2065749148
    Infant - Week 241,2451,487352,767
    Infant - Week 3682870169
    Infant - Week 481,1561,34212,499
    Infant - Week 608631,24902,112
    Infant - Week 7857630120

    Last Modified: Nov. 1, 2023, 4:05 p.m.
  • Visits (Subjects)


    Total number of subjectsAverage volume (ml) per subject
    Mother - Labor/Delivery4674.72
    Mother - Pre-entry4804.47
    Mother - Entry4964.76
    Mother - Infusion4375.10
    Mother - Week 623.00
    Mother - Week 124154.38
    Mother - Week 264054.74
    Mother - Week 483404.45
    Mother - Week 783064.49
    Infant - Birth4823.95
    Infant - Week 171.36
    Infant - Week 24281.05
    Infant - Week 64621.44
    Infant - Week 124161.27
    Infant - Week 163971.28
    Infant - Week 20291.12
    Infant - Week 244041.54
    Infant - Week 36271.52
    Infant - Week 483711.56
    Infant - Week 603531.22
    Infant - Week 78201.43
    Total number of subjectsAverage vials per subject
    Mother - Labor/Delivery4392.00
    Mother - Pre-entry4571.93
    Mother - Entry4681.93
    Mother - Infusion4172.01
    Mother - Week 621.50
    Mother - Week 124001.88
    Mother - Week 263871.86
    Mother - Week 483141.87
    Mother - Week 782721.90
    Infant - Birth4724.51
    Infant - Week 183.38
    Infant - Week 24183.24
    Infant - Week 64453.56
    Infant - Week 124083.48
    Infant - Week 163893.62
    Infant - Week 20272.74
    Infant - Week 243983.74
    Infant - Week 36253.48
    Infant - Week 483633.70
    Infant - Week 603463.61
    Infant - Week 78183.50
    Total number of subjectsAverage vials per subject
    Mother - Labor/Delivery3383.93
    Mother - Pre-entry134.00
    Mother - Entry3613.89
    Mother - Infusion3374.05
    Mother - Week 12183.78
    Mother - Week 262973.90
    Mother - Week 48233.70
    Mother - Week 78154.00
    Infant - Birth193.89
    Infant - Week 224.00
    Infant - Week 6183.94
    Infant - Week 1253.80
    Infant - Week 1633.00
    Infant - Week 2024.50
    Infant - Week 2484.38
    Infant - Week 4811.00

    Last Modified: Nov. 1, 2023, 4:05 p.m.